top of page

Mobilizing Oxygen, Transforming Lives.

A First-in-Class Oxygen Therapeutic

Our mission is to reverse hypoxia. Hypoxia occurs when the body's cells don't get enough oxygen, this plays a significant role in various fatal diseases. We are committed to patient safety and ensuring their access to life-saving oxygen therapeutics.

 Consistent Results

NuvOx Therapeutics is a clinical stage pharmaceutical company developing a drug that improves the flow of oxygen from lungs to blood and from blood to tissue. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy. The Company is currently enrolling 87 glioblastoma subjects in a prospective Phase IIb clinical trial to reverse tumor hypoxia; which increases radiation efficacy in association with chemoradiation treatment. The Company has received grant funding from NINDS to support evaluation of NanO₂ as a neuroprotectant by the Stroke Preclinical Assessment Network. The MHRA in the UK is supporting a Phase IIb clinical trial of NanO₂ in large vessel occlusion stroke. The trial will treat 150 stroke subjects and is scheduled to begin in 2024. BARDA is funding a Phase Ib clinical trial of NanO₂ in acute hypoxemic respiratory failure which will also start in 2024.

The NuvOx Team

NuvOx is guided by industry pioneers. Headquartered in Tucson, Arizona, we are scientists who have spent our careers pursuing novel and more effective therapeutics for patients.  

eberhard-grossgasteiger-J9NDmBVhN04-unsp

We would love to hear from you.

We are here to assist. A representative from NuvOx will follow up shortly.

bottom of page